Qiagen


Decent end to 2024

06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."

Pages
69
Language
English
Published on
06/02/25
You may also be interested by these reports :
17/11/26
Getinge delivered a mixed Q3 26, with sales marginally below consensus but adjusted EBITA well ahead. ACT drove a sharp margin step-up, even before ...

13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...

13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...

12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO